Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co ElifiledCriticalLilly Co Eli
Publication of AR119473A1publicationCriticalpatent/AR119473A1/en
Medicines That Contain Protein Lipid Enzymes And Other Medicines
(AREA)
Abstract
Se divulgan análogos de relaxina (RLN) que incluyen modificaciones que aumentan la semivida en comparación con la RLN humana nativa, que mantienen la selectividad para el receptor RXFP1 y que proporcionan estabilidad in vitro e in vivo para mejorar las propiedades de farmacología y reducir la inmunogenicidad. También se divulgan composiciones farmacéuticas que incluyen uno o más de los análogos de RLN descritos en la presente en un portador aceptable desde el punto de vista farmacéutico. También se divulgan métodos para elaborar y usar los análogos de RLN, en especial para tratar afecciones, enfermedades o trastornos cardiovasculares, pulmonares y/o renales.Relaxin (RLN) analogs are disclosed that include modifications that increase half-life compared to native human RLN, maintain selectivity for the RXFP1 receptor, and provide in vitro and in vivo stability to improve pharmacology properties and reduce immunogenicity. . Pharmaceutical compositions that include one or more of the RLN analogs described herein in a pharmaceutically acceptable carrier are also disclosed. Also disclosed are methods of making and using the RLN analogs, especially to treat cardiovascular, pulmonary, and/or renal conditions, diseases, or disorders.
ARP200102072A2019-07-312020-07-23
RELAXIN ANALOGS AND METHODS OF USING THEM
AR119473A1
(en)
Reduction of the viscosity of pharmaceutical formulations that comprise a therapeutic protein at a concentration of at least 70 mg / ml, where the therapeutic protein is not an antibody (divisional application 201700984)